Literature DB >> 2993431

Experimental parvoviral infection in humans.

M J Anderson, P G Higgins, L R Davis, J S Willman, S E Jones, I M Kidd, J R Pattison, D A Tyrrell.   

Abstract

Healthy adult volunteers were inoculated intranasally with human parvovirus obtained from an asymptomatic blood donor. One week after inoculation, intense viremia was observed in seronegative volunteers, accompanied by a mild illness with pyrexia, malaise, myalgia, itching, and excretion of virus from the respiratory tract. In the following week hematologic studies revealed reticulocytopenia with an associated slight drop in hemoglobin concentration, lymphopenia, neutropenia, and a drop in platelet counts. At 17-18 days after inoculation a second-phase illness with rash and arthralgia lasting three to four days occurred in three of four infected volunteers. This study confirms the etiologic role of human parvovirus in erythematous rash illness, with the second-phase illness being consistent with adult cases of erythema infectiosum. Moreover, the hematologic changes associated with infection support the hypothesis that the same virus is responsible for the temporary arrest of erythropoiesis that leads to aplastic crisis in persons with chronic hemolytic anemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993431     DOI: 10.1093/infdis/152.2.257

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  130 in total

1.  Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women.

Authors:  J A Jordan
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

Review 2.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

3.  Concurrent outbreaks of influenza and parvovirus B19 in a boys' boarding school.

Authors:  E A Grilli; M J Anderson; T W Hoskins
Journal:  Epidemiol Infect       Date:  1989-10       Impact factor: 2.451

4.  Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women.

Authors:  Allyson R Butchko; Jeanne A Jordan
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 5.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

6.  Parvovirus b19 infections and blood counts in blood donors.

Authors:  David Juhl; Dagmar Steppat; Siegfried Görg; Holger Hennig
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

7.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

Authors:  G J Kurtzman; B J Cohen; A M Field; R Oseas; R M Blaese; N S Young
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

8.  Polymerase chain reaction assay of parvovirus B19 DNA in clinical specimens.

Authors:  J P Clewley
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

9.  Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection.

Authors:  J R Kerr; M McCoy; B Burke; D L Mattey; V Pravica; I V Hutchinson
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

10.  Myeloid depression follows infection of susceptible newborn mice with the parvovirus minute virus of mice (strain i).

Authors:  J C Segovia; J A Bueren; J M Almendral
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.